deucravacitinib
bms
['deucra']
ab1117 #acr22 deucravacitinib: tyk2 inhibitor in active sle?
363 pt p2, double-blind pbo-controlled 48 wk study
deuc 3 mg bid, 6 bid, 12 qb vs pbo:
at 32wk: deuc 3bid &amp; 6bid &gt; pbo, sustained across all groups at 48wk.
aes: similar bw pbo and deuc. no vte #acrbest 
Rheumatologist at Institute for Rheumatic and Autoimmune Disease at Overlook Hospital, proud Hopkins alum, health care advocate, Eagles fan entering Giants land